FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068576769> ?p ?o ?g. }

• W2068576769 abstract "Background: Endocrine treatment-related adverse events have a strong impact on patients’ quality of life and sometimes result in treatment discontinuation. Since joint symptoms are the most frequently recognized side-effect of aromatase inhibitors, evaluation of associated risk factors may well be important. Among high body mass index (BMI) and chemotherapy have been associated with the development of joint symptoms in patients enrolled in ATAC trials. To determine the impact of these factors on treatment-emergent joint symptoms in Japanese breast cancer treated with adjuvant anastrozole, we conducted a prospective cohort study based on patient-reported outcomes (PROs). Patients and Methods: Postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled in this prospective cohort study (SAVS-JP, UMI02455). A total of 416 patients were recruited from 30 centers for PRO assessment at their after-care appointments between August 2009 and April 2012. Patients completed the self-report questionnaire at baseline, 3, 6, 9 and 12 months. Symptoms were assessed as four categories (none, Grade 1: somewhat, Grade 2: quite a bit, Grade 3: very much). Pre-existing symptoms were only included if they worsened from baseline. The endpoint of this study was the frequencies of treatment-related joint symptoms, which included reports of arthralgia, decrease of joint motion, and joint stiffness. Results: We obtained PROs from 391 (94.0%) of the 416 patients at baseline and at one or more points during treatment, so that 391 patients were analysed. Joint symptoms at baseline were reported by 134 (34.3%) patients and new or worsening symptoms were experienced by 258 (66.0%) patients. The symptoms were graded as: grade 1, 53.1%; grade 2, 37.6%; grade 3, 9.3%. Mean time to onset of joint symptoms was 5.4 months, and nearly 80% had developed symptoms by 6 months. Twelve patents discontinued treatment during the first year and two patients withdrew due to joint symptoms. Patients with joint symptoms were significantly younger (age: 63.1; standard deviation: 7.9) than those without symptoms (age: 65.8: 8.4; p = 0.0045). We categorized BMI into three groups (low: Discussion: The incidence of anastrozole-associated joint symptoms was more than 60%, with most women having developed symptoms by 6 months. The PROs may disclose higher prevalence rates than physician ratings for symptoms published in pivotal clinical trials. We found that younger age and adjuvant chemotherapy, but not high BMI, were significantly associated with joint symptoms. These data should prove useful for counseling before initiating treatment with adjuvant aromatase inhibitors for postmenopausal Japanese women. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-13-07." @default.
• W2068576769 created "2016-06-24" @default.
• W2068576769 creator A5004306855 @default.
• W2068576769 creator A5016055245 @default.
• W2068576769 creator A5019927163 @default.
• W2068576769 creator A5022487245 @default.
• W2068576769 creator A5029878775 @default.
• W2068576769 creator A5030317114 @default.
• W2068576769 creator A5030706881 @default.
• W2068576769 creator A5033354499 @default.
• W2068576769 creator A5038427152 @default.
• W2068576769 creator A5047231647 @default.
• W2068576769 creator A5064055618 @default.
• W2068576769 creator A5066441780 @default.
• W2068576769 creator A5067950730 @default.
• W2068576769 creator A5072489562 @default.
• W2068576769 creator A5077882995 @default.
• W2068576769 creator A5080265949 @default.
• W2068576769 creator A5080772866 @default.
• W2068576769 creator A5081108433 @default.
• W2068576769 creator A5088353595 @default.
• W2068576769 creator A5089979647 @default.
• W2068576769 date "2013-12-15" @default.
• W2068576769 modified "2023-09-26" @default.
• W2068576769 title "Abstract P1-13-07: Chemotherapy, but not body mass index has impact on joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes" @default.
• W2068576769 doi "https://doi.org/10.1158/0008-5472.sabcs13-p1-13-07" @default.
• W2068576769 hasPublicationYear "2013" @default.
• W2068576769 type Work @default.
• W2068576769 sameAs 2068576769 @default.
• W2068576769 citedByCount "1" @default.
• W2068576769 countsByYear W20685767692014 @default.
• W2068576769 crossrefType "proceedings-article" @default.
• W2068576769 hasAuthorship W2068576769A5004306855 @default.
• W2068576769 hasAuthorship W2068576769A5016055245 @default.
• W2068576769 hasAuthorship W2068576769A5019927163 @default.
• W2068576769 hasAuthorship W2068576769A5022487245 @default.
• W2068576769 hasAuthorship W2068576769A5029878775 @default.
• W2068576769 hasAuthorship W2068576769A5030317114 @default.
• W2068576769 hasAuthorship W2068576769A5030706881 @default.
• W2068576769 hasAuthorship W2068576769A5033354499 @default.
• W2068576769 hasAuthorship W2068576769A5038427152 @default.
• W2068576769 hasAuthorship W2068576769A5047231647 @default.
• W2068576769 hasAuthorship W2068576769A5064055618 @default.
• W2068576769 hasAuthorship W2068576769A5066441780 @default.
• W2068576769 hasAuthorship W2068576769A5067950730 @default.
• W2068576769 hasAuthorship W2068576769A5072489562 @default.
• W2068576769 hasAuthorship W2068576769A5077882995 @default.
• W2068576769 hasAuthorship W2068576769A5080265949 @default.
• W2068576769 hasAuthorship W2068576769A5080772866 @default.
• W2068576769 hasAuthorship W2068576769A5081108433 @default.
• W2068576769 hasAuthorship W2068576769A5088353595 @default.
• W2068576769 hasAuthorship W2068576769A5089979647 @default.
• W2068576769 hasConcept C121608353 @default.
• W2068576769 hasConcept C126322002 @default.
• W2068576769 hasConcept C143998085 @default.
• W2068576769 hasConcept C188816634 @default.
• W2068576769 hasConcept C197934379 @default.
• W2068576769 hasConcept C201903717 @default.
• W2068576769 hasConcept C2776215463 @default.
• W2068576769 hasConcept C2777176818 @default.
• W2068576769 hasConcept C2778504769 @default.
• W2068576769 hasConcept C2778715236 @default.
• W2068576769 hasConcept C2780221984 @default.
• W2068576769 hasConcept C530470458 @default.
• W2068576769 hasConcept C71924100 @default.
• W2068576769 hasConcept C72563966 @default.
• W2068576769 hasConceptScore W2068576769C121608353 @default.
• W2068576769 hasConceptScore W2068576769C126322002 @default.
• W2068576769 hasConceptScore W2068576769C143998085 @default.
• W2068576769 hasConceptScore W2068576769C188816634 @default.
• W2068576769 hasConceptScore W2068576769C197934379 @default.
• W2068576769 hasConceptScore W2068576769C201903717 @default.
• W2068576769 hasConceptScore W2068576769C2776215463 @default.
• W2068576769 hasConceptScore W2068576769C2777176818 @default.
• W2068576769 hasConceptScore W2068576769C2778504769 @default.
• W2068576769 hasConceptScore W2068576769C2778715236 @default.
• W2068576769 hasConceptScore W2068576769C2780221984 @default.
• W2068576769 hasConceptScore W2068576769C530470458 @default.
• W2068576769 hasConceptScore W2068576769C71924100 @default.
• W2068576769 hasConceptScore W2068576769C72563966 @default.
• W2068576769 hasLocation W20685767691 @default.
• W2068576769 hasOpenAccess W2068576769 @default.
• W2068576769 hasPrimaryLocation W20685767691 @default.
• W2068576769 hasRelatedWork W1119789418 @default.
• W2068576769 hasRelatedWork W1570320424 @default.
• W2068576769 hasRelatedWork W1971453032 @default.
• W2068576769 hasRelatedWork W1999793461 @default.
• W2068576769 hasRelatedWork W2000802899 @default.
• W2068576769 hasRelatedWork W2010448623 @default.
• W2068576769 hasRelatedWork W2015569024 @default.
• W2068576769 hasRelatedWork W2053311062 @default.
• W2068576769 hasRelatedWork W2128693265 @default.
• W2068576769 hasRelatedWork W2164154104 @default.
• W2068576769 hasRelatedWork W2191739491 @default.
• W2068576769 hasRelatedWork W2325489509 @default.
• W2068576769 hasRelatedWork W2329927582 @default.
• W2068576769 hasRelatedWork W2883132315 @default.
• W2068576769 hasRelatedWork W2914522939 @default.
• W2068576769 hasRelatedWork W2938608691 @default.
• W2068576769 hasRelatedWork W2944217343 @default.

• next